On April 30, 2024 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, reported it is presenting new data about its lead product candidate, PH-762, an INTASYL compound (Press release, Phio Pharmaceuticals, APR 30, 2024, View Source [SID1234642476]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PH-762 is currently being studied in a US clinical trial to assess safety and efficacy in specific skin cancers. (NCT 06014086). This open-label Phase 1b clinical study (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of IT PH-762 in Stages 1,2 and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma. Stages 1 and 2 cSCC represent 77% of all new cSCC annually. There are no drug products approved for treatment of Stages 1 and 2 cSCC.

The data will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) to be held in Chicago, Illinois.

Title: INTASYL PH-762: PD-1 Intratumoral Immunotherapy for Cutaneous Carcinoma

Poster Number: TPS9620
Topic: Melanoma/Skin Cancer
Presenting Author: Mary Spellman, M.D.
Date and Time: June 1, 2024: 1:30-4:30 PM CDT